Scarica l'app Stockscreener
3.52
3.83%
-0.14
Dopo l'orario di chiusura:
3.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SGHT Giù?
Forum
Previsione
Precedente Chiudi:
$3.66
Aprire:
$3.61
Volume 24 ore:
236.58K
Relative Volume:
0.73
Capitalizzazione di mercato:
$190.10M
Reddito:
$77.36M
Utile/perdita netta:
$-38.43M
Rapporto P/E:
-4.7516
EPS:
-0.7408
Flusso di cassa netto:
$-29.92M
1 W Prestazione:
-12.00%
1M Prestazione:
-37.37%
6M Prestazione:
+6.34%
1 anno Prestazione:
+56.44%
Intervallo 1D:
$3.4101
$3.61
Intervallo di 1 settimana:
$3.4101
$4.04
Portata 52W:
$2.03
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Nome
Sight Sciences Inc
Settore
Industria
Telefono
(415) 889-0550
Indirizzo
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.52 | 190.10M | 77.36M | -38.43M | -29.92M | -0.7408 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | Aggiornamento | Lake Street | Hold → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-11-04 | Downgrade | Lake Street | Buy → Hold |
| 2024-08-21 | Iniziato | Lake Street | Buy |
| 2023-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-04 | Iniziato | Needham | Hold |
| 2022-07-26 | Iniziato | Stifel | Hold |
| 2022-02-03 | Iniziato | William Blair | Outperform |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Sight Sciences Inc Borsa (SGHT) Ultime notizie
Sight Sciences wins $34M patent ruling against Alcon - MSN
Published on: 2026-04-05 14:40:16 - baoquankhu1.vn
SGHT SEC FilingsSight Sciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 8,168 Shares of Stock - MarketBeat
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) By Investing.com - Investing.com South Africa
Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares - MarketBeat
Sight Sciences (NASDAQ:SGHT) CEO Sells 29,244 Shares - MarketBeat
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) - Investing.com Australia
Sight Sciences CEO Badawi sells $108k in shares By Investing.com - Investing.com India
[Form 4] Sight Sciences, Inc. Insider Trading Activity - Stock Titan
Sight Sciences CEO Badawi sells $108k in shares - Investing.com
Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed - Stock Titan
Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations - Stock Titan
Sight Sciences executive plans $90K stock sale - National Today
Alison Bauerlein plans sale of 25,874 shares (SGHT) - Stock Titan
Insider sale notice: SGHT (NASDAQ: SGHT) 8,168 restricted shares - Stock Titan
SGHT PE Ratio & Valuation, Is SGHT Overvalued - Intellectia AI
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - The Manila Times
New dry eye data vs. Restasis joins Sight Sciences glaucoma studies at ASCRS - Stock Titan
SGHT (NASDAQ: SGHT) files Form 144 to sell 29,244 vested shares - Stock Titan
Proposed share sales at SGHT (NASDAQ: SGHT) include 2,293 and 576 shares - Stock Titan
Aug Rallies: Is Sight Sciences Inc a top pick in the sectorTrade Risk Summary & Target Return Focused Stock Picks - baoquankhu1.vn
Sight Sciences wins $34M in Alcon patent case, ongoing royalty By Investing.com - Investing.com South Africa
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - Yahoo Finance
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud - Law360
Lake Street Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Published on: 2026-03-31 02:42:17 - baoquankhu1.vn
Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - minichart.com.sg
Sight Sciences U.S. district court issued order on post-trial motions in patent infringement case against Alcon originally filed on Sep 16, 2021 - marketscreener.com
Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021 - TradingView
Sight Sciences Wins Infringement Lawsuit Against Alcon - National Today
Sight Sciences Wins Key Patent Ruling in Glaucoma Case - TipRanks
Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent - MarketScreener
Growth Value: Is Sight Sciences Inc on track to beat earnings2026 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aug Ideas: Is Sight Sciences Inc in a consolidation phase2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Sight Sciences Inc stock faces pressure amid weak Q4 guidance and slowing growth in eye care devices - AD HOC NEWS
Citigroup maintains Sight Sciences (SGHT) neutral recommendation - MSN
Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy - MSN
Can Sight Sciences Inc weather a recession2026 Technical Overview & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises - Investing.com Nigeria
Prosight Management LP Sells 431,746 Shares of Sight Sciences, Inc. $SGHT - MarketBeat
Morgan Stanley Sticks to Its Hold Rating for Sight Sciences (SGHT) - The Globe and Mail
Sight Sciences (SGHT) Q4 2025 Earnings Transcript - AOL.com
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 earnings call transcript - MSN
Sight Sciences Earnings Call Highlights Disciplined Growth - TipRanks
Stock Report: Can Sight Sciences Inc weather a recession2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Sight Sciences, Inc. (SGHT) reports Q4 loss, beats revenue estimates - MSN
S P Trends: Will Sight Sciences Inc outperform tech stocks2025 Bull vs Bear & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sight Sciences Inc Azioni (SGHT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):